18 Jan Anocca
Reagan Jarvis, Ph.D., CEO
April 21 | 9:15am | Gaudi 2 Ballroom
Anocca is leveraging its highly scalable precision analysis technologies to develop transformative TCR-T immunotherapies to treat cancer and other serious diseases. The company has pioneered a proprietary industrialised analytical cell biology platform that enables a deep understanding of disease specific T cell biology to deliver highly targeted cell-based therapies. Anocca has a fully integrated R&D infrastructure, with a range of scalable analytics platforms leveraging extensive libraries of engineered cells and complemented by a clinical manufacturing and process development facility. The company’s platform has generated a broad pipeline of high value assets focusing on distinct disease franchises. The company expects to progress several TCR-T therapies to the clinic. Anocca was founded in 2014 and has raised over $100M USD in funding from leading Nordic investors Swedbank Robur Ny Teknik, Ramsbury Invest, Mellby Gård, Nidoco, and Michano AB.